伊马替尼治疗儿童费城染色体阳性急性淋巴细胞白血病(EsPhALL2010):一项前瞻性、组间、开放标签、单臂临床试验
EsPhALL2010是一项在11个研究组开展的前瞻性单臂试验,155例1-17岁费城染色体阳性急性淋巴细胞白血病患者从诱导第15天起持续接受伊马替尼300 mg/m²联合化疗。5年无事件生存率为57.0%(95%CI 48.5-64.6),5年总生存率为71.8%(63.5-78.5);尽管移植比例低于EsPhALL2004,两研究生存相似,但早期持续伊马替尼可能增加毒性。
要点
- 从诱导第15天起持续伊马替尼300 mg/m²联合化疗,5年无事件生存率57.0%,总生存率71.8%。
- 59例(38%)在首次完全缓解期接受造血干细胞移植,低于EsPhALL2004。
- 154例严重不良事件发生于80例(52%)患者,最常见为感染(61例,39%)。
核心结论
- 尽管EsPhALL2010中接受HSCT的患者比例低于EsPhALL2004,但两研究的无事件生存和总生存相似。
- 作者认为,早期持续给予伊马替尼联合强化化疗可能增加毒性。
研究设计与样本
- 前瞻性、组间、开放标签、单臂临床试验(EsPhALL2010),在欧洲、智利和香港的11个研究组开展。
- 2010年1月1日至2014年12月31日入组155例1-17岁t(9;22)(q34;q11)急性淋巴细胞白血病患者,均纳入各国一线试验。
- 患者从诱导第15天起持续接受伊马替尼300 mg/m²直至化疗期间;HSCT资格取决于早期形态学反应和微小残留病。
- 共同主要终点为无事件生存和总生存,按意向性治疗人群分析。
主要发现
- 151例(97%)在诱导后达首次完全缓解,4例在巩固后达缓解;按EsPhALL风险分层,102例(66%)为好风险,53例(34%)为差风险。
- 59例(38%)在首次完全缓解期接受HSCT;40例(26%)复发,41例(26%)死亡(25例[61%]死于持续完全缓解期,16例[39%]死于复发后)。
- 5年无事件生存率为57.0%(95%CI 48.5-64.6),5年总生存率为71.8%(95%CI 63.5-78.5)。
- 80例(52%)患者报告154例严重不良事件;最常见毒性为感染(61例[39%],多为细菌性),胃肠道疾病10例(6%),骨坏死8例(5%)。
- 严重不良事件主要发生于高危方案和延迟强化期间,包括14例致死性事件(巩固期1例、高危方案6例、第一次延迟强化6例、第二次延迟强化1例)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The EsPhALL2004 randomised trial showed a 10% advantage in disease-free survival for short, discontinuous use of imatinib after induction compared with no use of imatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia receiving Berlin-Frankfurt-Münster chemotherapy and haemopoietic stem-cell transplantation (HSCT). Other contemporary studies showed an advantage from continuous protracted exposure to imatinib, challenging the indications to transplant. The EsPhALL2010 study was designed to assess whether imatinib given from day 15 of induction and continuously throughout chemotherapy led to a different outcome to that obtained in EsPhALL2004, despite decreasing the number of patients having HSCT. METHODS: This prospective, intergroup, open-label, single-arm clinical trial (EsPhALL2010) was done at 11 study groups across Europe, Chile, and Hong Kong. Patients aged 1-17 years with the translocation t(9;22)(q34;q11) who were recruited into national front-line trials for acute lymphoblastic leukaemia were eligible for this trial. Patients with abnormal renal or hepatic function or an active systemic infection were ineligible. Patients received imatinib 300 mg/m2 continuously from day 15 of induction during chemotherapy. Eligibility to HSCT depended on early morphological response and minimal residual disease. Imatinib was recommended throughout the first year after transplant. The co-primary endpoints were event-free survival and overall survival. All analyses were done in the intention-to-treat population. The trial is registered with the European Clinical Trials Database (EudraCT 2004-001647-30) and with ClinicalTrials.gov (NCT00287105) and is completed. FINDINGS: 158 patients were screened for eligibility, of whom 155 were enrolled between Jan 1, 2010, and Dec 31, 2014. 151 (97%) patients achieved first complete remission after induction and four after the consolidation phase, with 102 (66%) patients categorised as good risk and 53 (34%) as poor risk according to EsPhALL risk stratification criteria. 59 (38%) patients had HSCT during their first complete remission. 40 (26%) patients relapsed and 41 (26%) patients died during the study (25 [61%] during complete continuous remission, and 16 [39%] after relapse). The 5-year event-free survival was 57·0% (95% CI 48·5-64·6) and 5-year overall survival was 71·8% (63·5-78·5). 154 serious adverse events were reported in 80 (52%) of 155 patients. The most common toxicity was infection (61 [39%] patients, mostly bacterial); gastrointestinal disorders occurred in ten (6%) patients and osteonecrosis in eight (5%). Serious adverse events occurred mainly during high-risk blocks and delayed intensifications, including 14 fatal events (one in the consolidation phase, six in high-risk blocks, six in first delayed intensification, and one in second delayed intensification). INTERPRETATION: Although HSCT was done in a smaller proportion of patients in EsPhALL2010 than in EsPhALL2004, event-free and overall survival were similar between the two studies. Our data suggest that imatinib given early and continuously with intensive chemotherapy might increase toxicity. FUNDING: Projet Hospitalier de Recherche Clinique-Cancer and Novartis France; Bloodwise and Cancer Research UK; Ministry of Health, Czech Republic.
引用
- Biondi A, Gandemer V, De Lorenzo P, et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol. 2018. PMID: 30501871. doi:10.1016/S2352-3026(18)30173-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。